Generation Bio Co., a genetic medicines company focused on R&D of a new class of gene therapy for the treatment of several rare and prevalent diseases, announced data from a study related to the use of the company’s cell-targeted lipid nanoparticle (ctLNP) system for the treatment of hemophilia A. Hemophilia A is an inherited, hereditary bleeding condition caused by a deficiency of... https://www.coherentmarketinsights.com/news/generation-bio-achieves-two-milestones-in-non-viral-gene-therapy-for-the-treatment-of-hemophilia-a-249